{"protocolSection":{"identificationModule":{"nctId":"NCT06480110","orgStudyIdInfo":{"id":"Ebas0001"},"organization":{"fullName":"Rigshospitalet, Denmark","class":"OTHER"},"briefTitle":"Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer","officialTitle":"Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-20","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-12-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-12-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-11-18","studyFirstSubmitQcDate":"2024-06-26","studyFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-26","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Helle Pappot","investigatorTitle":"Professor","investigatorAffiliation":"Rigshospitalet, Denmark"},"leadSponsor":{"name":"Rigshospitalet, Denmark","class":"OTHER"},"collaborators":[{"name":"Danish Cancer Society","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is an open-label phase I/II study evaluating the addition of ebastine to docetaxel in the treatment for metastatic castration resistant prostate cancer.\n\nPatients will be randomized in a 2:1 fashion to receive ebastine daily during and after treatment with a maximum of 10 courses of docetaxel.\n\nThe primary endpoint is change in the profile of urinary and blood lipids to indicate absorption and possible efficacy of ebastine.\n\nSecondary endpoints include PSA response and radiologic progression free survival.","detailedDescription":"The complete study protocol can be studied by contacting the authors."},"conditionsModule":{"conditions":["Metastatic Castration-resistant Prostate Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention","type":"EXPERIMENTAL","description":"Standard docetaxel (10 cycles) plus ebastine daily","interventionNames":["Drug: Docetaxel + Ebastine"]},{"label":"Comparator","type":"ACTIVE_COMPARATOR","description":"Standard docetaxel (10 cycles) without ebastine","interventionNames":["Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Docetaxel + Ebastine","description":"Ebastine is administered once daily.","armGroupLabels":["Intervention"],"otherNames":["Kestine (Ebastine)"]},{"type":"DRUG","name":"Docetaxel","description":"docetaxel every three weeks","armGroupLabels":["Comparator"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Changes in the profile and concentration of urinary lipids and blood lipids","description":"Measurement of lipid species concentration, focusing on Bis(monoacylglycero)phosphate and lysophospholipids in urine and blood, before, during, and after treatment, compared to PSA levels, radiologic response, and control group results.","timeFrame":"Blood+urine samples are collected at baseline, at evaluation scans (after 4th and 7th cycles), and at the end of treatment (after 10 Docetaxel cycles, upon progression before 10 cycles, or at study discontinuation). Each cycle is 21 days."}],"secondaryOutcomes":[{"measure":"radiologic progression-free survival","description":"Radiologic progression-free survival is defined as ≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 9 weeks after enrolment, and/or progression in nodes or viscera on cross-sectional imaging as defined by RECIST 1.1 (see below), or death.","timeFrame":"By comparing with a baseline scan, the treatment effect and disease status will be evaluated with a scan after the 4th and 7th cycles, at end of treatment undtil study completion. Each cycle is 21 days. A patient will receive a maximum of 10 cycles."},{"measure":"PSA response","description":"Prostate-Specific Antigen (PSA) Response criteria according to Prostate Cancer Working Group (PCWG3) 3rd edition","timeFrame":"PSA response will be monitored during treatment, compared to radiologic response after the 4th and 7th cycles, and at treatment completion (maximum 10 cycles/progression/discontinuation). Each cycle lasts 21 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 1. Have a histologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate (carcinomas with pure small-cell histology or pure high grade neuroendocrine histology are excluded; neuroendocrine differentiation is allowed).\n\n  2. Surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL equivalent to 1.7 nmol/L. For patients, currently being treated with luteinizing hormone-releasing hormone (LHRH) agonists, i.e., patients who have not undergone an orchiectomy, therapy must be continued throughout the study.\n\n  3. Have evidence of disease progression after prior therapy for mCRPC:\n\nDisease progression after initiation of most recent therapy is based on any of the following criteria:\n\n* Rise in PSA: a minimum of 2 consecutive rising levels, with an interval of ≥ 1 week between each determination. The most recent screening measurement must have been ≥ 2 ng/mL\n* Transaxial imaging: new or progressive soft tissue masses on CT or MRI scans as defined by RECIST 1.1\n* Radionuclide bone scan: at least 2 new metastatic lesions 4. Signed informed consent obtained prior to initiation of any study-specific procedures or treatment 5. Age ≥ 18 years 6. Life expectancy ≥ 3 months 7. Performance status 0 - 1 8. Adequate organ functions\n\n  1. Hematological: absolute neutrophil count (ANC) \\>1.5 x 109/L, platelet count \\>100 x 109/L, hemoglobin \\> 6,2 mmol/L\n  2. Hepatic: Bilirubin within normal range, aspartate transaminase (AST) and alanine transaminase (ALT) \\<2.5 upper normal lever, albumin \\> 25 g/L\n  3. Renal: creatinine clearance \\>30 mL/min/1.73m2\n\n     Exclusion Criteria:\n\n     - 1. History of significant gastric or small bowel resection, malabsorption syndrome, or other lack of integrity of the upper gastrointestinal tract that may prevent compliance with oral drug administration 2. Presence of any serious concomitant systemic disorders and/or psychiatric condition incompatible with the study (at the investigator's discretion) 3. Presence of any active infection (at the investigator's discretion). 4. Central nervous system (CNS) disease including epilepsy or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study procedures.\n\n     5. Concurrent use of cationic amphiphilic drugs (see appendix A) including over-the-counter medication.\n\n     6. Use of other investigational drug 7. Allergic reaction to any of the included drugs","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Helle Pappot, DMsc","role":"CONTACT","phone":"+4535458403","email":"helle.pappot@regionh.dk"}],"overallOfficials":[{"name":"Helle Pappot, DMsc","affiliation":"Rigshospitalet, Denmark","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Department of Oncology 5073, Rigshospitalet","status":"RECRUITING","city":"Copenhagen","zip":"2100","country":"Denmark","contacts":[{"name":"Helle Pappot, MD, DMSc","role":"CONTACT","phone":"0045 35454222","email":"helle.pappot@regionh.dk"},{"name":"Helle Pappot, MD, DMSc","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":55.67594,"lon":12.56553}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000011471","term":"Prostatic Neoplasms"}],"ancestors":[{"id":"D000005834","term":"Genital Neoplasms, Male"},{"id":"D000014565","term":"Urogenital Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000005832","term":"Genital Diseases, Male"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000011469","term":"Prostatic Diseases"},{"id":"D000052801","term":"Male Urogenital Diseases"}],"browseLeaves":[{"id":"M14335","name":"Prostatic Neoplasms","asFound":"Prostate Cancer","relevance":"HIGH"},{"id":"M8946","name":"Genital Neoplasms, Male","relevance":"LOW"},{"id":"M17315","name":"Urogenital Neoplasms","relevance":"LOW"},{"id":"M2876","name":"Genital Diseases","relevance":"LOW"},{"id":"M8944","name":"Genital Diseases, Male","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M14333","name":"Prostatic Diseases","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"C000058249","term":"Ebastine"}],"ancestors":[{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000050257","term":"Tubulin Modulators"},{"id":"D000050256","term":"Antimitotic Agents"},{"id":"D000050258","term":"Mitosis Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000006634","term":"Histamine H1 Antagonists"},{"id":"D000006633","term":"Histamine Antagonists"},{"id":"D000018494","term":"Histamine Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1668","name":"Docetaxel","asFound":"Physical","relevance":"HIGH"},{"id":"M340424","name":"Ebastine","asFound":"Injections, Intravenous","relevance":"HIGH"},{"id":"M26197","name":"Tubulin Modulators","relevance":"LOW"},{"id":"M26196","name":"Antimitotic Agents","relevance":"LOW"},{"id":"M9708","name":"Histamine","relevance":"LOW"},{"id":"M9710","name":"Histamine H1 Antagonists","relevance":"LOW"},{"id":"M212144","name":"Histamine phosphate","relevance":"LOW"},{"id":"M9709","name":"Histamine Antagonists","relevance":"LOW"},{"id":"M20504","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}